KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Assets Average (2019 - 2025)

Vir Biotechnology's Assets Average history spans 7 years, with the latest figure at $1.0 billion for Q4 2025.

  • On a quarterly basis, Assets Average fell 30.2% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 billion, a 30.2% decrease, with the full-year FY2025 number at $1.2 billion, down 27.62% from a year prior.
  • Assets Average hit $1.0 billion in Q4 2025 for Vir Biotechnology, down from $1.1 billion in the prior quarter.
  • Over the last five years, Assets Average for VIR hit a ceiling of $2.8 billion in Q2 2022 and a floor of $1.0 billion in Q4 2025.
  • Historically, Assets Average has averaged $1.8 billion across 5 years, with a median of $1.7 billion in 2024.
  • Biggest five-year swings in Assets Average: soared 151.06% in 2022 and later plummeted 32.1% in 2024.
  • Tracing VIR's Assets Average over 5 years: stood at $1.6 billion in 2021, then surged by 73.74% to $2.7 billion in 2022, then fell by 27.9% to $2.0 billion in 2023, then decreased by 26.91% to $1.4 billion in 2024, then plummeted by 30.2% to $1.0 billion in 2025.
  • Business Quant data shows Assets Average for VIR at $1.0 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.3 billion in Q2 2025.